Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Dabigatran and Amiodarone
NCT02171026Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2006
- Primary completion
- Jun 2006
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of dabigatran in Atrial fibrillation (AFib) and venous thromboembolism (VTE) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration time curve of the analyte in plasma over one steady state dosing interval at Day 4, Maximum concentration of the analyte in plasma at steady state at Day 4 and 6 more. Started Apr 2006; status: completed.
02
Drugs
dabigatran
03
Conditions
Atrial fibrillation (AFib)venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT02171026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02171026.